Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$22.68
-$0.97(-11.96%)
At close: 4:00 PM EST
$22.68
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$7.96 - $49.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.00M
Market Cap
$6.10B
Enterprise Value$2.40B
Total Cash (Recent Filing)$373.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding132,743,260
10 Day Avg. Volume2,445,922
30 Day Avg. Volume3,999,629
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.80
Forecast
1Y Price Target
$56.83Price Target Upside150.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late‑stage Clinical MomentumA clustered late‑stage program with staggered pivotal readouts and Breakthrough Therapy designation materially reduces single‑trial binary risk and creates multiple regulatory and commercial inflection points. Robust powering and Part B follow‑up improve chances of durable efficacy and label breadth, supporting long‑term market entry plans.
Solid Near‑term Liquidity RunwayA multi‑year cash runway provides durable financial flexibility to complete multiple Phase III programs and fund commercialization readiness without immediate dependency on dilutive bridge financings. This allows management to execute trials, regulatory interactions and launch planning while absorbing near‑term operational spending increases.
Material Equity Raise Strengthens Balance SheetA large primary equity offering materially increases long‑term funding capacity to support R&D, NDA prep and commercial build. While dilutive, the structural effect is enhanced liquidity and the ability to invest in launch infrastructure and manufacturing scale, reducing execution risk tied to funding gaps.
Bears Say
Pre‑revenue, Sustained Cash BurnOperating losses and persistent negative free cash flow create a structural reliance on equity capital to fund operations. Even with new proceeds, repeated rounds or large financings may be required for commercialization, raising dilution risk and pressuring long‑term capital efficiency until product revenue materializes.
Trial Design/placebo‑response RiskA high placebo signal from earlier trials is a structural clinical risk that can blunt observed treatment effects and complicate regulatory interpretation. Even with Phase III design adjustments, persistent placebo dynamics could reduce effect sizes, affect statistical success, and increase the probability of additional studies or label restrictions.
Regulatory, Payer And Coding UncertaintyUncertainty on NDA strategy, FDA discussions and post‑approval coding/reimbursement pathways are durable commercialization risks. Even with positive efficacy, unclear payer coverage and coding could limit access, constrain pricing and slow adoption, materially impacting long‑term revenue realization and clinic economics.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics, Inc.’s price range in the past 12 months?
Definium Therapeutics, Inc. lowest stock price was $7.96 and its highest was $49.20 in the past 12 months.
What is Definium Therapeutics, Inc.’s market cap?
Definium Therapeutics, Inc.’s market cap is $6.10B.
When is Definium Therapeutics, Inc.’s upcoming earnings report date?
Definium Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 21 days.
How were Definium Therapeutics, Inc.’s earnings last quarter?
Definium Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.492 by -$0.218.
Is Definium Therapeutics, Inc. overvalued?
According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued.
Does Definium Therapeutics, Inc. pay dividends?
Definium Therapeutics, Inc. does not currently pay dividends.
What is Definium Therapeutics, Inc.’s EPS estimate?
Definium Therapeutics, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. has 132,743,260 shares outstanding.
What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?
Definium Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.492. Following the earnings report the stock price went down -4.957%.
Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.83 (150.59% Upside)
$56.83 (150.59% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
451.98%
12-Months-Change
Fundamentals
Return on Equity
-102.48%
Trailing 12-Months
Asset Growth
45.75%
Trailing 12-Months
Company Description
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
DFTX Stock 12 Month Forecast
Average Price Target
$56.83
▲(150.59% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.82% Insiders
8.02% Mutual Funds
0.05% Other Institutional Investors
81.37% Public Companies and Individual Investors